Despite advances in the treatment of patients with advanced clear-cell renal cell carcinoma (ccRCC) with anti-angiogenic agents, checkpoint inhibitors, and mammalian target of rapamycin (mTOR) inhibitors alone and in combination, durable responses are seen in about 30% of treated ccRCC patients [1,2,3,4,5,6,7,8,9,10,11,12,13]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.